ATTR-CM Under Siege ⚔️ Vutrisiran's Defense 🛡️ Victory for the Heart 🏆

🚨 New Insights from HELIOS-B 🫀✨   In patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM), the RNA interference therapy vutrisiran not only reduced mortality and cardiovascular events, but also showed measurable benefits in cardiac structure and function over 30 months.   📉 Thinner LV walls & lower LV mass index 💪 Preserved ejection fraction & stroke volume ⚙️ Improved diastolic function – better E/e′ & e′ velocity 🏆 Benefits seen even with substantial tafamidis use   These findings support early initiation of vutrisiran to protect the heart and slow disease progression.   #Cardiology #HeartFailure #ATTRCM #RNAi #Vutrisiran #HELIOSB #Echocardiography #HeartHealth ❤️